ALB and metabolic dysfunction-associated steatotic liver disease: Moreover, IGF-I has a well-described function in lowering insulin resistance, that plays a pivotal role in the pathogenesis of NAFLD[43] and has been shown to increase albumin levels after 120 days of subcutaneous administration in cirrhotic patients [44].